AI주식인사이트AI Stock Insight
C

툴젠

199800KOSDAQ

45.4 / 100

Reference Date: 2026-09-08

Financial Score14.5 / 40
News Sentiment16.9 / 25
Momentum4.0 / 20
Disclosure10.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Declined 7.7% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

Toolgen specializes in gene-editing R&D, patent monetization, and the development of therapeutics and functional seeds using CRISPR/Cas9 and other technologies. As the world's only company to develop three types of gene-editing tools (ZFN, TALEN, CRISPR/Cas9), it leads in therapeutic drug development (e.g., TGT-001, TG-wAMD) and functional crop seed innovation (e.g., high-oleic soybeans, disease-resistant potatoes).

Number of Employees

66people

Average Salary

72.3M KRW

Score Calculation Basis

Detailed Financial Score

PER
—Industry Average 15.004.0Point
PBR
5.61Industry Average 1.200.0Point

4.7x industry avg (risky)

ROE
-64.34Industry Average 8.000.0Point

Well below industry avg

Debt Ratio
2.89Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~20252.5 / 10 points
Revenue Growth Rate
2.5 / 3

Avg ▲13.7% (2-year basis)

Operating Profit Growth Rate
0.0 / 3

Avg ▼17.2% (2-year basis)

ROE Trend
0.0 / 4

Avg ROE -44.8% (improving, 3yr)

Detailed News Sentiment

2 totalPositive 1Neutral 1Negative 0Average Sentiment Score 67.5

Detailed Momentum

52-week position1.0Point

Near 52w low (1%, downtrend)

Current 34,800Won52-week high 138,20052-week low 33,150
1-month return1.0Point

1m -7.69% (falling)

Volume trend2.0Point

Volume decreasing

Detailed Disclosure

9 totalPositive 0Neutral 9Negative 0
  • Neutral[기재정정]투자설명서2026-09-04
  • Neutral효력발생안내( 2026.8.20. 제출 증권신고서(지분증권) )2026-09-04
  • Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-09-01
  • Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-08-28
  • Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-08-28